TSE:MDP Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis C$2.93 -0.13 (-4.25%) As of 07/11/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Medexus Pharmaceuticals Stock (TSE:MDP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MDP alerts:Sign Up Key Stats Today's RangeC$2.89▼C$3.1250-Day RangeC$2.50▼C$3.4052-Week RangeC$1.71▼C$5.56Volume24,029 shsAverage Volume78,828 shsMarket CapitalizationC$65.60 millionP/E Ratio14.01Dividend YieldN/APrice TargetC$5.49Consensus RatingBuy Company Overview Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action. Read More Receive MDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MDP Stock News HeadlinesMedexus Pharmaceuticals Inc (TSX:MDP) Q4 2025: Everything You Need To Know Ahead Of EarningsJune 27, 2025 | finance.yahoo.comMedexus Pharmaceuticals Inc (TSX:MDP) Q4 2025 Earnings Report Preview: What To Look ForJune 26, 2025 | finance.yahoo.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.July 12 at 2:00 AM | Porter & Company (Ad)Should We Be Delighted With Medexus Pharmaceuticals Inc.'s (TSE:MDP) ROE Of 11%?April 18, 2025 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - MDPJanuary 29, 2025 | finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - MDPJanuary 29, 2025 | ca.finance.yahoo.comDespite the downward trend in earnings at Medexus Pharmaceuticals (TSE:MDP) the stock spikes 16%, bringing one-year gains to 48%December 25, 2024 | finance.yahoo.comShould We Be Cautious About Medexus Pharmaceuticals Inc.'s (TSE:MDP) ROE Of 7.0%?November 10, 2024 | finance.yahoo.comSee More Headlines MDP Stock Analysis - Frequently Asked Questions How have MDP shares performed this year? Medexus Pharmaceuticals' stock was trading at C$3.46 at the start of the year. Since then, MDP shares have decreased by 15.3% and is now trading at C$2.93. How do I buy shares of Medexus Pharmaceuticals? Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Medexus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medexus Pharmaceuticals investors own include AutoZone (AZO), Cisco Systems (CSCO), Facedrive (FDVRF), Intel (INTC), kneat.com (KSI), NIO (NIO) and Nanotech Security (NTS). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:MDP CIKN/A Webwww.medexus.com Phone877-633-3987FaxN/AEmployees98Year FoundedN/APrice Target and Rating Average Price Target for Medexus PharmaceuticalsC$5.49 High Price TargetC$8.25 Low Price TargetC$3.45 Potential Upside/Downside+87.3%Consensus RatingBuy Rating Score (0-4)3.29 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)C$0.21 Trailing P/E Ratio14.01 Forward P/E Ratio17.94 P/E GrowthN/ANet IncomeC$3.26 million Net Margins3.25% Pretax MarginN/A Return on Equity11.07% Return on Assets4.89% Debt Debt-to-Equity Ratio120.58 Current Ratio1.01 Quick RatioN/A Sales & Book Value Annual SalesC$100.25 million Price / Sales0.65 Cash FlowN/A Price / Cash FlowN/A Book ValueC$1.35 per share Price / Book2.17Miscellaneous Outstanding Shares22,388,156Free FloatN/AMarket CapC$65.60 million OptionableNot Optionable Beta1.96 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (TSE:MDP) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medexus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.